CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.
Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, explains the rationale behind the clinical endpoints of the Company’s CUV105 vitiligo study, as well as the program’s pathway to market.
Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, provided insights into the Company’s R&D pipeline at the Capital Markets Briefing that took place in Sydney in May.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the recent results from the CUV151 study, looking at whether afamelanotide can reduce and repair photodamage (skin damage induced by ultraviolet radiation) in healthy volunteers.
CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...
CLINUVEL held a webinar to discuss the Company’s financial results for the year ended 30 June 2024 and its diversification plans for long-term sustainability.